SSY Group gets NMPA approvals for two new drugs

SSY Group Limited has received approval from the National Medical Products Administration (NMPA) for the production and registration of Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)). Classified as a type 4 chemical drug, this product is intended for treating various ophthalmic conditions including blepharitis, conjunctivitis, and keratitis, and is also approved for perioperative aseptic chemotherapy in ophthalmology. This approval is deemed to have passed consistency evaluation and expands the Group’s range of ophthalmic preparations.

In a separate development, SSY Group also obtained NMPA approval for Compound Sodium Picosulfate Granules (10mg of Sodium Picosulfate per bag). This type 3 drug, also passing consistency evaluation, is primarily indicated for bowel cleansing before procedures such as colonoscopy, X-ray examinations, and surgical interventions.

These approvals follow the Group's earlier announcement on 4 December 2025, which confirmed the NMPA registration approval for its Sodium Picosulfate bulk drug, allowing it to serve as a bulk drug for preparations already available in the market.